but I don't need e.g., an oncologist to know everything BCL2 interacts with. I need them to
- know what BCL2 mutations mean as far as prognosis and treatment options
- be able to explain to me what the prognosis and treatment options are
- respect my values for my own care and enforce informed...
- know what BCL2 mutations mean as far as prognosis and treatment options
- be able to explain to me what the prognosis and treatment options are
- respect my values for my own care and enforce informed...
May 7, 2025 at 11:02 PM
but I don't need e.g., an oncologist to know everything BCL2 interacts with. I need them to
- know what BCL2 mutations mean as far as prognosis and treatment options
- be able to explain to me what the prognosis and treatment options are
- respect my values for my own care and enforce informed...
- know what BCL2 mutations mean as far as prognosis and treatment options
- be able to explain to me what the prognosis and treatment options are
- respect my values for my own care and enforce informed...
High-grade B-cell lymphoma shows a lower CNS relapse risk than expected, with distinct patterns in gene expression subgroups.
by Alduaij W, Jiang A (...) Savage KJ et 15 al. in Blood #MedSky
📖 read the article:
by Alduaij W, Jiang A (...) Savage KJ et 15 al. in Blood #MedSky
📖 read the article:
CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature–expressing DLBCL
Key PointsCNS relapse rate in HGBCL-DH-BCL2 (6.8% at 2 years) is much lower than previously reported and is associated with clinical risk factors.DZsig ref
ashpublications.org
February 15, 2025 at 10:30 AM
High-grade B-cell lymphoma shows a lower CNS relapse risk than expected, with distinct patterns in gene expression subgroups.
by Alduaij W, Jiang A (...) Savage KJ et 15 al. in Blood #MedSky
📖 read the article:
by Alduaij W, Jiang A (...) Savage KJ et 15 al. in Blood #MedSky
📖 read the article:
Interesting study on how to sensitize myeloma cells to the BCL2 inhibitor venetoclax by interfering with signal transduction pathways. #myeloma #science 🩸🔬https://www.nature.com/articles/s41408-025-01215-x
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention - Blood Cancer Journal
Blood Cancer Journal - Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
www.nature.com
May 4, 2025 at 8:54 AM
Excited that this is finally out! Great work by Jared Field for his PhD. @chrimanitoba.bsky.social @dream-diabetes.bsky.social www.tandfonline.com/doi/full/10....
The mitophagy receptor BNIP3L/Nix coordinates nuclear calcium signaling to modulate the muscle phenotype
Mitochondrial quality control is critical in muscle to ensure contractile and metabolic function. BNIP3L/Nix is a BCL2 member, a mitophagy receptor, and has been implicated in muscle atrophy. Human...
www.tandfonline.com
March 24, 2025 at 12:52 PM
Excited that this is finally out! Great work by Jared Field for his PhD. @chrimanitoba.bsky.social @dream-diabetes.bsky.social www.tandfonline.com/doi/full/10....
New paper led by Aimilia Vareli out now.
nature.com/articles/s41...
The lymphoma microenvironment stops BH3-mimetics working.
In vitro/vivo/silico, we find inhibition of NFκB makes BH3-mimetics great again.🧵
@sussexbcr.bsky.social @bsmsmedschool.bsky.social @leukaemiauk.bsky.social @sussexcancer.org
nature.com/articles/s41...
The lymphoma microenvironment stops BH3-mimetics working.
In vitro/vivo/silico, we find inhibition of NFκB makes BH3-mimetics great again.🧵
@sussexbcr.bsky.social @bsmsmedschool.bsky.social @leukaemiauk.bsky.social @sussexcancer.org
Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL - Cell Death & Disease
Cell Death & Disease - Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL
nature.com
August 18, 2025 at 11:05 AM
New paper led by Aimilia Vareli out now.
nature.com/articles/s41...
The lymphoma microenvironment stops BH3-mimetics working.
In vitro/vivo/silico, we find inhibition of NFκB makes BH3-mimetics great again.🧵
@sussexbcr.bsky.social @bsmsmedschool.bsky.social @leukaemiauk.bsky.social @sussexcancer.org
nature.com/articles/s41...
The lymphoma microenvironment stops BH3-mimetics working.
In vitro/vivo/silico, we find inhibition of NFκB makes BH3-mimetics great again.🧵
@sussexbcr.bsky.social @bsmsmedschool.bsky.social @leukaemiauk.bsky.social @sussexcancer.org
Online now! Online now! Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer #chembiol
Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer
Drug repurposing can uncover unexpected therapeutic opportunities in cancer. Li et al. identify the antiviral drug simeprevir as an inhibitor of KPNB1-mediated NF-κB signaling, uncovering a KPNB1-p65-BCL2 survival axis and establishing simeprevir as a promising therapeutic lead.
dlvr.it
July 31, 2026 at 3:30 PM
Online now! Online now! Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer #chembiol
Next, he discussed the design of a Bcl-2 inhibitor that is highly selective over Bcl-xL. (4/5) www.sciencedirect.com/science/arti...
A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax
BCL2 is a key pro-survival protein that is overexpressed in many cancers. The first generation BCL2 inhibitor venetoclax has proved highly effective i…
www.sciencedirect.com
October 7, 2025 at 2:50 PM
Next, he discussed the design of a Bcl-2 inhibitor that is highly selective over Bcl-xL. (4/5) www.sciencedirect.com/science/arti...
Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial showed. https://www.medpagetoday.com/hematologyoncology/lymphoma/122957
Study Warns on Venetoclax in Double-Hit Lymphoma
Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen
www.medpagetoday.com
September 15, 2026 at 2:11 AM
Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial showed. https://www.medpagetoday.com/hematologyoncology/lymphoma/122957
Delighted that our work describing a potential novel treatment approach for B-cell Acute Lymphoblastic Leukaemia is published today in @natcomms.nature.com. 🧵
www.nature.com/articles/s41...
www.nature.com/articles/s41...
CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition - Nature Communications
CREBBP mutations in B-cell acute lymphoblastic leukemia (B-ALL) are linked to poor prognosis and chemoresistance. Here, the authors show that genetic or pharmacological inactivation of CREBBP sensitiz...
www.nature.com
May 20, 2025 at 9:34 AM
Delighted that our work describing a potential novel treatment approach for B-cell Acute Lymphoblastic Leukaemia is published today in @natcomms.nature.com. 🧵
www.nature.com/articles/s41...
www.nature.com/articles/s41...
RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance https://www.biorxiv.org/content/10.1101/2025.02.02.636108v1
February 8, 2025 at 6:51 AM
RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance https://www.biorxiv.org/content/10.1101/2025.02.02.636108v1
• Bcl2-L-13 plays a protective role in the pressure-overloaded heart
• Bcl2-L-13 is involved in mitophagy and mitochondrial fission in vivo
• AMPKα2 is the responsible kinase to phosphorylate Bcl2-L-13 at Ser272
www.sciencedirect.com/science/arti...
• Bcl2-L-13 is involved in mitophagy and mitochondrial fission in vivo
• AMPKα2 is the responsible kinase to phosphorylate Bcl2-L-13 at Ser272
www.sciencedirect.com/science/arti...
November 25, 2024 at 8:39 AM
• Bcl2-L-13 plays a protective role in the pressure-overloaded heart
• Bcl2-L-13 is involved in mitophagy and mitochondrial fission in vivo
• AMPKα2 is the responsible kinase to phosphorylate Bcl2-L-13 at Ser272
www.sciencedirect.com/science/arti...
• Bcl2-L-13 is involved in mitophagy and mitochondrial fission in vivo
• AMPKα2 is the responsible kinase to phosphorylate Bcl2-L-13 at Ser272
www.sciencedirect.com/science/arti...
#TemporoMandibularJoint #OsteoArthritis
#FGF9/FGFR3 acts downstream of ⬆️VWA1 in Compensatory responses (⏫ColII ACAN BCL2) of Condylar Cartilage in rat +0.5-mm Zr occlusal plate on molars
& Chondrocyte +6% #CyclicStretch
#ArthritisRes 2025
arthritis-research.biomedcentral.com/articles/10....
#FGF9/FGFR3 acts downstream of ⬆️VWA1 in Compensatory responses (⏫ColII ACAN BCL2) of Condylar Cartilage in rat +0.5-mm Zr occlusal plate on molars
& Chondrocyte +6% #CyclicStretch
#ArthritisRes 2025
arthritis-research.biomedcentral.com/articles/10....
July 18, 2025 at 7:38 PM
#TemporoMandibularJoint #OsteoArthritis
#FGF9/FGFR3 acts downstream of ⬆️VWA1 in Compensatory responses (⏫ColII ACAN BCL2) of Condylar Cartilage in rat +0.5-mm Zr occlusal plate on molars
& Chondrocyte +6% #CyclicStretch
#ArthritisRes 2025
arthritis-research.biomedcentral.com/articles/10....
#FGF9/FGFR3 acts downstream of ⬆️VWA1 in Compensatory responses (⏫ColII ACAN BCL2) of Condylar Cartilage in rat +0.5-mm Zr occlusal plate on molars
& Chondrocyte +6% #CyclicStretch
#ArthritisRes 2025
arthritis-research.biomedcentral.com/articles/10....
📊 Research Summary: In a phase 3 trial, adding tucidinostat to standard immunochemotherapy improved event-free survival in patients with MYC/BCL2 double-expressor #DiffuseLargeBCellLymphoma.
ja.ma/42KX54a
ja.ma/42KX54a
May 22, 2026 at 1:00 PM
📊 Research Summary: In a phase 3 trial, adding tucidinostat to standard immunochemotherapy improved event-free survival in patients with MYC/BCL2 double-expressor #DiffuseLargeBCellLymphoma.
ja.ma/42KX54a
ja.ma/42KX54a
Just stumbled on this 💎 of a paper at my end-of-the-year review of the #apoptosis #Bax #Bcl2 literature (i.e., trying to get that last paper out). Can't stress enough how glad I am that this gets reported and has a venue in a high profile journal! 🔬🧪👍👍👍 @natureportfolio.bsky.social
Why Bax detection in >1400 publications might be flawed - Cell Death & Disease
Cell Death & Disease - Why Bax detection in >1400 publications might be flawed
www.nature.com
December 23, 2024 at 2:22 PM
Just stumbled on this 💎 of a paper at my end-of-the-year review of the #apoptosis #Bax #Bcl2 literature (i.e., trying to get that last paper out). Can't stress enough how glad I am that this gets reported and has a venue in a high profile journal! 🔬🧪👍👍👍 @natureportfolio.bsky.social
The viral BCL2 protein BHRF1 of Epstein–Barr virus promotes AIM2 inflammasome activation to facilitate lytic replication
journals.plos.org/plospathogen...
journals.plos.org/plospathogen...
September 25, 2025 at 2:27 AM
The viral BCL2 protein BHRF1 of Epstein–Barr virus promotes AIM2 inflammasome activation to facilitate lytic replication
journals.plos.org/plospathogen...
journals.plos.org/plospathogen...
Our work on dual BTK and BCL2 inhibition in marginal zone lymphoma, using the new BTK degrader BGB-16673 and the BCL2 inhibitor sonrotoclax, is now available on @biorxivpreprint.bsky.social @iorbellinzona.bsky.social @usi.ch
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclax
Background: BTK and BCL2 represent key therapeutic targets in B-cell lymphomas, including marginal zone lymphoma (MZL). Here, we evaluated the novel BTK degrader BGB-16673, and the second-generation B...
www.biorxiv.org
November 27, 2025 at 6:41 AM
Our work on dual BTK and BCL2 inhibition in marginal zone lymphoma, using the new BTK degrader BGB-16673 and the BCL2 inhibitor sonrotoclax, is now available on @biorxivpreprint.bsky.social @iorbellinzona.bsky.social @usi.ch
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Don't miss Silke Johannsen, Roland K. O. Sigel et al's recent article
#ChemSciCovers
'Elucidating the solution structure of the monomolecular BCL2 RNA G-quadruplex: a new robust NMR assignment approach'
🔗 doi.org/10.1039/D5SC...
#ChemSciCovers
'Elucidating the solution structure of the monomolecular BCL2 RNA G-quadruplex: a new robust NMR assignment approach'
🔗 doi.org/10.1039/D5SC...
June 8, 2025 at 9:00 AM
Don't miss Silke Johannsen, Roland K. O. Sigel et al's recent article
#ChemSciCovers
'Elucidating the solution structure of the monomolecular BCL2 RNA G-quadruplex: a new robust NMR assignment approach'
🔗 doi.org/10.1039/D5SC...
#ChemSciCovers
'Elucidating the solution structure of the monomolecular BCL2 RNA G-quadruplex: a new robust NMR assignment approach'
🔗 doi.org/10.1039/D5SC...
ZNF831, by inhibiting STAT3/Bcl2, promotes apoptosis & enhances chemosensitivity to #Capecitabine & #Gemcitabine, highlighting it as a novel tumor suppressor, potential #Biomarker & #TherapeuticTarget for #BreastCancer.
#OpenAccess: doi.org/10.1016/j.ge...
#OpenAccess: doi.org/10.1016/j.ge...
December 17, 2025 at 1:25 AM
ZNF831, by inhibiting STAT3/Bcl2, promotes apoptosis & enhances chemosensitivity to #Capecitabine & #Gemcitabine, highlighting it as a novel tumor suppressor, potential #Biomarker & #TherapeuticTarget for #BreastCancer.
#OpenAccess: doi.org/10.1016/j.ge...
#OpenAccess: doi.org/10.1016/j.ge...
Lithium, used 25+ years, could modify dementia. Works by boosting Bcl2, BDNF, inhibiting GSK3β, not just fixing amyloid or tau. PMID:42268602, JAMA Psychiatry 2026, @JAMAPsych https://doi.org/10.1001/jamapsychiatry.2026.1296 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1001/jamapsychiatry.2026.1296
No description available
doi.org
July 20, 2026 at 7:00 PM
“TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways”
A promising therapeutic strategy for ENZ- resistant PCa ⤵️
www.nature.com/articles/s41...
A promising therapeutic strategy for ENZ- resistant PCa ⤵️
www.nature.com/articles/s41...
TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways - Cell Death & Differentiation
Cell Death & Differentiation - TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways
www.nature.com
June 17, 2026 at 10:21 AM
“TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways”
A promising therapeutic strategy for ENZ- resistant PCa ⤵️
www.nature.com/articles/s41...
A promising therapeutic strategy for ENZ- resistant PCa ⤵️
www.nature.com/articles/s41...
Cul5Wsb2 uses BCL2 proteins as co-receptors to target Bim for degradation. https://www.biorxiv.org/content/10.1101/2025.08.14.670414v1
August 15, 2025 at 2:46 AM
Cul5Wsb2 uses BCL2 proteins as co-receptors to target Bim for degradation. https://www.biorxiv.org/content/10.1101/2025.08.14.670414v1
How specific structural differences of Bcl2 proteins modulate the interaction with BH3 domains and apoptotic function https://www.biorxiv.org/content/10.64898/2026.07.17.739112v1
July 17, 2026 at 9:53 PM
How specific structural differences of Bcl2 proteins modulate the interaction with BH3 domains and apoptotic function https://www.biorxiv.org/content/10.64898/2026.07.17.739112v1
The FDA granted accelerated approval to sonrotoclax (Beqalzi) as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma (MCL), a rare and often aggressive subtype of non-Hodgkin lymphoma.
https://www.medpagetoday.com/hematologyoncology/lymphoma/121256
https://www.medpagetoday.com/hematologyoncology/lymphoma/121256
Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma
Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma
www.medpagetoday.com
May 14, 2026 at 8:49 PM
The FDA granted accelerated approval to sonrotoclax (Beqalzi) as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma (MCL), a rare and often aggressive subtype of non-Hodgkin lymphoma.
https://www.medpagetoday.com/hematologyoncology/lymphoma/121256
https://www.medpagetoday.com/hematologyoncology/lymphoma/121256
📊 Research Summary: In a phase 3 trial, adding tucidinostat to standard immunochemotherapy improved event-free survival in patients with MYC/BCL2 double-expressor #DiffuseLargeBCellLymphoma.
ja.ma/41RTvET
ja.ma/41RTvET
April 22, 2026 at 3:20 PM
📊 Research Summary: In a phase 3 trial, adding tucidinostat to standard immunochemotherapy improved event-free survival in patients with MYC/BCL2 double-expressor #DiffuseLargeBCellLymphoma.
ja.ma/41RTvET
ja.ma/41RTvET